Back to Journals » Cancer Management and Research » Volume 12

Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review

Authors Yan Z, Yao ZH, Yao SN, Xia QX, Wang HY, Chu JF, Song M, Zhao S, Liu YY

Received 15 March 2020

Accepted for publication 8 July 2020

Published 27 July 2020 Volume 2020:12 Pages 6311—6316

DOI https://doi.org/10.2147/CMAR.S254007

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Xueqiong Zhu


Zheng Yan,1 Zhi-Hua Yao,1 Shu-Na Yao,1 Qing-Xin Xia,2 Hai-Ying Wang,1 Jun-Feng Chu,1 Ming Song,1 Shuang Zhao,1 Yan-Yan Liu1

1Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China; 2Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China

Correspondence: Yan-Yan Liu
Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, No. 127 Dongming Road, Zhengzhou, Henan 450008, People’s Republic of China
Tel/ Fax +86 371-65587791
Email yyliu@zzu.edu.cn

Abstract: Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.

Keywords: primary mediastinal large B-cell lymphoma, immunotherapy, radiotherapy, nivolumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]